Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Liver Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 172 articles:
HTML format



Single Articles


    March 2024
  1. HILDT E, Hu J
    New facet of CARs: HBV-specific CARs as inhibitors of virus morphogenesis and release.
    Gut. 2024;73:566-567.
    PubMed    


  2. TARGHER G, Byrne CD, Tilg H
    MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Gut. 2024;73:691-702.
    PubMed     Abstract available


    February 2024
  3. LEE HH, Lee HA, Kim EJ, Kim HY, et al
    Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Gut. 2024;73:533-540.
    PubMed     Abstract available


  4. CUBERO FJ, Sarobe P, Tiegs G
    Advancing with cancer immunotherapeutics: CD29(+) regulatory T cell antagonism.
    Gut. 2024;73:391-392.
    PubMed    


  5. GREEN BL, Myojin Y, Ma C, Ruf B, et al
    Immunosuppressive CD29(+) Treg accumulation in the liver in mice on checkpoint inhibitor therapy.
    Gut. 2024;73:509-520.
    PubMed     Abstract available


  6. HUNTER H, Johnston AJ, Said W, Wong NA, et al
    Colonic spider naevi in a middle-aged man.
    Gut. 2024;73:441-520.
    PubMed    


  7. QIAN Z, Liang J, Huang R, Song W, et al
    HBV integrations reshaping genomic structures promote hepatocellular carcinoma.
    Gut. 2024 Feb 23:gutjnl-2023-330414. doi: 10.1136/gutjnl-2023-330414.
    PubMed     Abstract available


  8. EL-SERAG H, Kanwal F, Ning J, Powell H, et al
    Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
    Gut. 2024 Feb 16:gutjnl-2024-332034. doi: 10.1136/gutjnl-2024-332034.
    PubMed     Abstract available


  9. KEATING CR, Calvisi DF, Qiu W
    High-fat diet-induced AKT-palmitoylation in hepatocellular carcinoma: a breakthrough mechanistic investigation.
    Gut. 2024 Feb 9:gutjnl-2023-331857. doi: 10.1136/gutjnl-2023-331857.
    PubMed    


    January 2024
  10. HE T, Zhang D
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.
    Gut. 2024 Jan 22:gutjnl-2023-331443. doi: 10.1136/gutjnl-2023-331443.
    PubMed    


  11. BARCENA-VARELA M, Berraondo P
    Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma.
    Gut. 2024 Jan 9:gutjnl-2023-331647. doi: 10.1136/gutjnl-2023-331647.
    PubMed    



  12. Correction: P23 Opportunistic cirrhosis case finding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high-risk group.
    Gut. 2024;73:e3.
    PubMed    


  13. KONG M, Zhou J, Kang A, Kuai Y, et al
    Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis.
    Gut. 2024 Jan 4:gutjnl-2023-329671. doi: 10.1136/gutjnl-2023-329671.
    PubMed     Abstract available


    December 2023
  14. YANG TC, Chen WC, Hou MC, Chen PH, et al
    Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial.
    Gut. 2023 Dec 14:gutjnl-2023-330419. doi: 10.1136/gutjnl-2023-330419.
    PubMed     Abstract available


  15. CAI N, Cheng K, Ma Y, Liu S, et al
    Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8(+) T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.
    Gut. 2023 Dec 13:gutjnl-2023-331342. doi: 10.1136/gutjnl-2023-331342.
    PubMed     Abstract available


  16. HEINEN N, Khanal R, Westhoven S, Klohn M, et al
    Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses.
    Gut. 2023 Dec 12:gutjnl-2023-330961. doi: 10.1136/gutjnl-2023-330961.
    PubMed    


  17. YU X, Pfefferkorn M, van Bommel F, Zhang X, et al
    Clinical applications of circulating HBV RNA as a potential surrogate biomarker for intrahepatic cccDNA transcriptional activity.
    Gut. 2023 Dec 11:gutjnl-2023-331217. doi: 10.1136/gutjnl-2023-331217.
    PubMed    


  18. CHOUIK Y, Levrero M
    Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block.
    Gut. 2023;73:10-11.
    PubMed    


    November 2023
  19. LI R, Liu X, Huang X, Zhang D, et al
    Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis.
    Gut. 2023 Nov 30:gutjnl-2023-330243. doi: 10.1136/gutjnl-2023-330243.
    PubMed     Abstract available


  20. ZHANG X, Yip TC, Wong GL, Leow WX, et al
    Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
    Gut. 2023;72:2364-2371.
    PubMed     Abstract available


  21. RODERBURG C, Kostev K, Mertens A, Luedde T, et al
    Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer.
    Gut. 2023;72:2383-2384.
    PubMed    


  22. EN LI CHO E, Ang CZ, Quek J, Fu CE, et al
    Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
    Gut. 2023;72:2138-2148.
    PubMed     Abstract available



  23. Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023;72:e4.
    PubMed    


    October 2023
  24. BRENNAN PN, Zelber-Sagi S, Allen AM, Dillon JF, et al
    Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.
    Gut. 2023 Oct 28:gutjnl-2023-330771. doi: 10.1136/gutjnl-2023-330771.
    PubMed    


  25. ARECHEDERRA M, Casadei Gardini A, Raggi C
    More than shots in the dark: improving patient stratification to move closer to personalised therapies in intrahepatic cholangiocarcinoma.
    Gut. 2023 Oct 27:gutjnl-2023-331119. doi: 10.1136/gutjnl-2023-331119.
    PubMed    


  26. JUANOLA A, Ma AT, de Wit K, Gananandan K, et al
    Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.
    Gut. 2023 Oct 26:gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923.
    PubMed     Abstract available


  27. TESTONI B, Scholtes C, Plissonnier ML, Paturel A, et al
    Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
    Gut. 2023 Oct 25:gutjnl-2023-330644. doi: 10.1136/gutjnl-2023-330644.
    PubMed     Abstract available


  28. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    PubMed     Abstract available


  29. MUKHOPADHYA I
    Is HBx protein the X factor in the pathogenesis of IBD?
    Gut. 2023;72:1808-1809.
    PubMed    


  30. CIOCAN D, Turpin W
    New insights into an old paradigm: why IgA accumulates in alcoholic liver disease and what could be its role.
    Gut. 2023;72:1812-1814.
    PubMed    


  31. AVILA MA
    MicroRNA-223: a key regulator of liver tumour microenvironment.
    Gut. 2023;72:1811-1812.
    PubMed    


    September 2023
  32. MANTOVANI A, Tilg H, Targher G
    FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials.
    Gut. 2023 Sep 27:gutjnl-2023-331115. doi: 10.1136/gutjnl-2023-331115.
    PubMed    


  33. O'ROURKE CJ, Salati M, Rae C, Carpino G, et al
    Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
    Gut. 2023 Sep 27:gutjnl-2023-330748. doi: 10.1136/gutjnl-2023-330748.
    PubMed     Abstract available


  34. RAMADORI P, Gallage S, Heikenwalder MF
    Unique tumour microenvironment: when ferroptosis activation boosts ICI of liver cancer.
    Gut. 2023;72:1639-1641.
    PubMed    


  35. LUXENBURGER H, Thimme R
    SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease.
    Gut. 2023;72:1783-1794.
    PubMed     Abstract available


  36. CONCHE C, Finkelmeier F, Pesic M, Nicolas AM, et al
    Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade.
    Gut. 2023;72:1774-1782.
    PubMed     Abstract available


    August 2023
  37. FAN Z, Jin M, Zhang L, Wang N, et al
    From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification.
    Gut. 2023 Aug 7:gutjnl-2023-330461. doi: 10.1136/gutjnl-2023-330461.
    PubMed     Abstract available


  38. MARJOT T, Tomlinson JW, Hodson L, Ray DW, et al
    Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD.
    Gut. 2023;72:1607-1619.
    PubMed     Abstract available


  39. GRETEN TF
    'Invisible' immune checkpoint molecule causing resistance to anti-PD1 therapy in HCC.
    Gut. 2023;72:1440-1441.
    PubMed    


    July 2023
  40. ZHAO L, Wu Q, Li Q, Chen A, et al
    TIPSS plus extrahepatic collateral embolisation may decrease variceal rebleeding and post-TIPSS hepatic encephalopathy.
    Gut. 2023 Jul 31:gutjnl-2023-330255. doi: 10.1136/gutjnl-2023-330255.
    PubMed    


  41. HE X, Gao N, Lv F, Wu F, et al
    Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.
    Gut. 2023 Jul 24:gutjnl-2023-330271. doi: 10.1136/gutjnl-2023-330271.
    PubMed    


  42. WANG X, Huang H, Sze KM, Wang J, et al
    S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos.
    Gut. 2023;72:1370-1384.
    PubMed     Abstract available


  43. MANTOVANI A, Csermely A, Tilg H, Byrne CD, et al
    Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals.
    Gut. 2023;72:1433-1436.
    PubMed    


  44. BYRNE CD, Targher G
    Time to consider a holistic approach to the treatment of non-alcoholic fatty liver disease in obese young people?
    Gut. 2023;72:1238-1239.
    PubMed    


    June 2023
  45. POTENZA A, Balestrieri C, Spiga M, Albarello L, et al
    Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.
    Gut. 2023 Jun 30:gutjnl-2022-328042. doi: 10.1136/gutjnl-2022-328042.
    PubMed     Abstract available


  46. WITTKOP L, Boettler T
    More than shots in the dark: driving vaccine efficacy in cirrhosis.
    Gut. 2023 Jun 7:gutjnl-2023-329867. doi: 10.1136/gutjnl-2023-329867.
    PubMed    


  47. FISCHER A, Ozdirik B, Geisel D, Malinka T, et al
    Gastric variceal bleeding in a patient with alcohol abuse: business as usual?
    Gut. 2023;72:1038-1114.
    PubMed    


    May 2023
  48. ZHANG Q, Ye M, Lin C, Hu M, et al
    Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study.
    Gut. 2023;72:996-1006.
    PubMed     Abstract available


    April 2023
  49. LEWINSKA M, Karhus ML, Ellegaard AG, Romero-Gomez M, et al
    Serum lipidome unravels a diagnostic potential in bile acid diarrhoea.
    Gut. 2023 Apr 18:gutjnl-2022-329213. doi: 10.1136/gutjnl-2022-329213.
    PubMed     Abstract available


  50. XIONG Z, Chan SL, Zhou J, Vong JSL, et al
    Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
    Gut. 2023 Apr 5:gutjnl-2022-328364. doi: 10.1136/gutjnl-2022-328364.
    PubMed     Abstract available


    March 2023
  51. GIRALDEZ-GALLEGO A, Rodriguez-Seguel EDP, Valencia-Martin R, Morillo-Garcia A, et al
    Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial.
    Gut. 2023 Mar 24:gutjnl-2022-328222. doi: 10.1136/gutjnl-2022-328222.
    PubMed     Abstract available


  52. CAMILLERI M, El-Omar EM
    Ten reasons gastroenterologists and hepatologists should be treating obesity.
    Gut. 2023 Mar 21:gutjnl-2023-329639. doi: 10.1136/gutjnl-2023-329639.
    PubMed    


  53. LOOMBA R, Huang DQ, Sanyal AJ, Anstee QM, et al
    Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
    Gut. 2023;72:581-589.
    PubMed     Abstract available


  54. SIMON TG, Roelstraete B, Alkhouri N, Hagstrom H, et al
    Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease.
    Gut. 2023;72:573-580.
    PubMed     Abstract available


  55. WANG S, Feng R, Wang SS, Liu H, et al
    FOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression.
    Gut. 2023;72:549-559.
    PubMed     Abstract available


    February 2023
  56. WEISS E, de la Pena-Ramirez C, Aguilar F, Lozano JJ, et al
    Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023 Feb 14:gutjnl-2022-328708. doi: 10.1136/gutjnl-2022-328708.
    PubMed     Abstract available


  57. KANE SV, Reau N
    Clinical advances: pregnancy in gastroenterologic and hepatic conditions.
    Gut. 2023 Feb 9:gutjnl-2022-328893. doi: 10.1136/gutjnl-2022-328893.
    PubMed     Abstract available


    January 2023
  58. HENDRIKX T, Lang S, Rajcic D, Wang Y, et al
    Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice.
    Gut. 2023 Jan 23:gutjnl-2022-328265. doi: 10.1136/gutjnl-2022-328265.
    PubMed     Abstract available


  59. RAVAIOLI F, Dajti E, Mantovani A, Newsome PN, et al
    Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Gut. 2023 Jan 4:gutjnl-2022-328689. doi: 10.1136/gutjnl-2022-328689.
    PubMed     Abstract available


  60. CHEN S, Huang C, Liao G, Sun H, et al
    Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences.
    Gut. 2023 Jan 3:gutjnl-2022-328428. doi: 10.1136/gutjnl-2022-328428.
    PubMed     Abstract available


  61. FU Y, Mackowiak B, Feng D, Lu H, et al
    MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression.
    Gut. 2023 Jan 2:gutjnl-2022-327924. doi: 10.1136/gutjnl-2022-327924.
    PubMed     Abstract available


  62. ITZEL T, Falconer T, Daza J, Roig A, et al
    Letter to the editor: vaccination against upper respiratory infections is a matter of survival in alcoholic liver disease.
    Gut. 2023;72:208-209.
    PubMed    


  63. MONTIRONI C, Castet F, Haber PK, Pinyol R, et al
    Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
    Gut. 2023;72:129-140.
    PubMed     Abstract available


  64. HERNAEZ R, Peck-Radosavljevic M
    MAFLD, HCC and the dilemma of (changing) terminology in liver diseases.
    Gut. 2023;72:9-11.
    PubMed    


    December 2022
  65. LATIF MU, Schmidt GE, Mercan S, Rahman R, et al
    NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression.
    Gut. 2022;71:2561-2573.
    PubMed     Abstract available


  66. RAO J, Wang H, Ni M, Wang Z, et al
    FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2.
    Gut. 2022;71:2539-2550.
    PubMed     Abstract available


    November 2022
  67. TAN Z, Chiu MS, Yang X, Yue M, et al
    Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
    Gut. 2022 Nov 30:gutjnl-2022-327133. doi: 10.1136/gutjnl-2022-327133.
    PubMed     Abstract available


  68. BAJAJ JS, Pena-Rodriguez M, La Reau A, Phillips W, et al
    Longitudinal transkingdom gut microbial approach towards decompensation in outpatients with cirrhosis.
    Gut. 2022 Nov 7. pii: gutjnl-2022-328403. doi: 10.1136/gutjnl-2022-328403.
    PubMed     Abstract available


  69. THEVENOT T, Desmarets M, Weil D, Di Martino V, et al
    Diameter of the shunt: the missing link in the appraisal of pTIPS in patients with cirrhosis with previous hepatic encephalopathy.
    Gut. 2022 Nov 3. pii: gutjnl-2022-328761. doi: 10.1136/gutjnl-2022-328761.
    PubMed    


  70. DUFOUR JF, Marjot T, Becchetti C, Tilg H, et al
    COVID-19 and liver disease.
    Gut. 2022;71:2350-2362.
    PubMed     Abstract available


  71. KASPER P, Lang S, Demir M, Steffen HM, et al
    Optimising the management of cardiovascular comorbidities in NAFLD patients: it's time to (re-) act!
    Gut. 2022;71:2365-2366.
    PubMed    


    September 2022
  72. KULKARNI AV, Metage CS, Gora BA, Tirumalle S, et al
    SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis.
    Gut. 2022 Sep 16. pii: gutjnl-2022-328451. doi: 10.1136/gutjnl-2022-328451.
    PubMed    


  73. RUDLER M, Hernandez-Gea V, Procopet BD, Giraldez A, et al
    Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding.
    Gut. 2022 Sep 9. pii: gutjnl-2022-326975. doi: 10.1136/gutjnl-2022-326975.
    PubMed     Abstract available


  74. LI X, Pan J, Liu T, Yin W, et al
    Novel TCF21(high) pericyte subpopulation promotes colorectal cancer metastasis by remodelling perivascular matrix.
    Gut. 2022 Sep 7:gutjnl-2022-327913. doi: 10.1136/gutjnl-2022-327913.
    PubMed     Abstract available


  75. ZHAO Y, Yeo YH, Samaan J, Lv F, et al
    Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19.
    Gut. 2022 Sep 5. pii: gutjnl-2022-328188. doi: 10.1136/gutjnl-2022-328188.
    PubMed    


  76. JOHN BV, Bastaich DR, Ferreira RD, Doshi A, et al
    COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis.
    Gut. 2022 Sep 5:gutjnl-2022-327799. doi: 10.1136/gutjnl-2022-327799.
    PubMed    


  77. BYRNE CD, Targher G
    Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed.
    Gut. 2022;71:1695-1696.
    PubMed    


  78. SIMON TG, Roelstraete B, Hagstrom H, Sundstrom J, et al
    Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
    Gut. 2022;71:1867-1875.
    PubMed     Abstract available


    August 2022

  79. Correction: Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2022;71:e9.
    PubMed    


  80. LIU N, Wang X, Steer CJ, Song G, et al
    MicroRNA-206 promotes the recruitment of CD8(+) T cells by driving M1 polarisation of Kupffer cells.
    Gut. 2022;71:1642-1655.
    PubMed     Abstract available


  81. ZHOU L, Yu KH, Wong TL, Zhang Z, et al
    Lineage tracing and single-cell analysis reveal proliferative Prom1+ tumour-propagating cells and their dynamic cellular transition during liver cancer progression.
    Gut. 2022;71:1656-1668.
    PubMed     Abstract available


  82. REVIA S, Seretny A, Wendler L, Banito A, et al
    Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
    Gut. 2022;71:1613-1628.
    PubMed     Abstract available


  83. LAUER GM
    Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers.
    Gut. 2022 Aug 1. pii: gutjnl-2022-327761. doi: 10.1136/gutjnl-2022-327761.
    PubMed    


    July 2022
  84. MONIN MB, Baier L, Berger M, Gorny JG, et al
    SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination.
    Gut. 2022 Jul 26. pii: gutjnl-2022-328169. doi: 10.1136/gutjnl-2022-328169.
    PubMed    


  85. ANGELINI G, Panunzi S, Castagneto-Gissey L, Pellicano F, et al
    Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
    Gut. 2022 Jul 12. pii: gutjnl-2022-327498. doi: 10.1136/gutjnl-2022-327498.
    PubMed     Abstract available


  86. BUCH S, Innes H, Lutz PL, Nischalke HD, et al
    Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.
    Gut. 2022 Jul 4. pii: gutjnl-2022-327196. doi: 10.1136/gutjnl-2022-327196.
    PubMed     Abstract available


  87. GRACIA-SANCHO J, Dufour JF
    NTCP: a pharmacological target for multiple liver conditions.
    Gut. 2022;71:1248-1250.
    PubMed    


  88. PAVLIDES M, Mozes FE, Harrison SA
    Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1453-1454.
    PubMed    


  89. SALHAB A, Amer J, Lu Y, Safadi R, et al
    Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.
    Gut. 2022;71:1373-1385.
    PubMed     Abstract available


    June 2022
  90. MORITA S, Duda DG
    Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
    Gut. 2022 Jun 30. pii: gutjnl-2022-327782. doi: 10.1136/gutjnl-2022-327782.
    PubMed    


  91. BEA S, Jeong HE, Park S, Yu OHY, et al
    Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study.
    Gut. 2022 Jun 20. pii: gutjnl-2022-327504. doi: 10.1136/gutjnl-2022-327504.
    PubMed    


  92. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    PubMed     Abstract available


  93. MITHIEUX G
    Transcription factor p63, a member of the p53 family of tumour suppressors, regulates hepatic glucose metabolism.
    Gut. 2022 Jun 15. pii: gutjnl-2022-327790. doi: 10.1136/gutjnl-2022-327790.
    PubMed    


  94. SULLIVAN KM, Jiang X, Guha P, Lausted C, et al
    Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases.
    Gut. 2022 Jun 15. pii: gutjnl-2021-325808. doi: 10.1136/gutjnl-2021-325808.
    PubMed     Abstract available


  95. UCHE-ANYA E, Anyane-Yeboa A, Berzin TM, Ghassemi M, et al
    Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity.
    Gut. 2022 Jun 10. pii: gutjnl-2021-326271. doi: 10.1136/gutjnl-2021-326271.
    PubMed     Abstract available


  96. MAJUMDAR A, Tsochatzis EA
    Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1236-1237.
    PubMed    


    May 2022
  97. MARCHI E, Ramamurthy N, Ansari MA, Harrer CE, et al
    Defining the key intrahepatic gene networks in HCV infection driven by sex.
    Gut. 2022 May 25. pii: gutjnl-2021-326314. doi: 10.1136/gutjnl-2021-326314.
    PubMed     Abstract available


  98. DHAR A, Haboubi HN, Attwood SE, Auth MKH, et al
    British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.
    Gut. 2022 May 23. pii: gutjnl-2022-327326. doi: 10.1136/gutjnl-2022-327326.
    PubMed     Abstract available


  99. MARTIN-SERRANO MA, Kepecs B, Torres-Martin M, Bramel ER, et al
    Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Gut. 2022 May 18. pii: gutjnl-2021-326514. doi: 10.1136/gutjnl-2021-326514.
    PubMed     Abstract available


  100. GONZALEZ-RELLAN MJ, Novoa E, da Silva Lima N, Rodriguez A, et al
    Hepatic p63 regulates glucose metabolism by repressing SIRT1.
    Gut. 2022 May 17. pii: gutjnl-2021-326620. doi: 10.1136/gutjnl-2021-326620.
    PubMed     Abstract available


  101. RIVOLTINI L, Bhoori S, Camisaschi C, Bergamaschi L, et al
    Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers.
    Gut. 2022 May 4. pii: gutjnl-2021-326869. doi: 10.1136/gutjnl-2021-326869.
    PubMed    


  102. MOZES FE, Lee JA, Selvaraj EA, Jayaswal ANA, et al
    Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
    Gut. 2022;71:1006-1019.
    PubMed     Abstract available


  103. TAMAKI N, Munaganuru N, Jung J, Yonan AQ, et al
    Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
    Gut. 2022;71:983-990.
    PubMed     Abstract available


    April 2022
  104. HERNAEZ R, Avila MA
    Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
    Gut. 2022 Apr 26. pii: gutjnl-2022-327132. doi: 10.1136/gutjnl-2022-327132.
    PubMed    


  105. ZHAO Y, Ren X, Lu J, He M, et al
    Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids.
    Gut. 2022 Apr 22. pii: gutjnl-2021-326617. doi: 10.1136/gutjnl-2021-326617.
    PubMed    


  106. HOHMANN N, Schroder F, Moreira B, Teng H, et al
    Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease.
    Gut. 2022;71:842-844.
    PubMed    


  107. SMATI S, Polizzi A, Fougerat A, Ellero-Simatos S, et al
    Integrative study of diet-induced mouse models of NAFLD identifies PPARalpha as a sexually dimorphic drug target.
    Gut. 2022;71:807-821.
    PubMed     Abstract available


  108. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
    Gut. 2022;71:778-788.
    PubMed     Abstract available


    March 2022
  109. ZHANG C, Li J, Cheng Y, Meng F, et al
    Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients.
    Gut. 2022 Mar 31. pii: gutjnl-2021-325915. doi: 10.1136/gutjnl-2021-325915.
    PubMed     Abstract available


  110. JUANOLA A, Mezzano G, Hamilton JP, Gines P, et al
    Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data".
    Gut. 2022;71:657-658.
    PubMed    


  111. HADERER M, Neubert P, Rinner E, Scholtis A, et al
    Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.
    Gut. 2022;71:580-592.
    PubMed     Abstract available


  112. RHA MS, Han JW, Koh JY, Lee HS, et al
    Impaired antibacterial response of liver sinusoidal Vgamma9(+)Vdelta2(+) T cells in patients with chronic liver disease.
    Gut. 2022;71:605-615.
    PubMed     Abstract available


    February 2022
  113. LU LG, Zhou ZL, Wang XY, Liu BY, et al
    PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma.
    Gut. 2022 Feb 16. pii: gutjnl-2021-326350. doi: 10.1136/gutjnl-2021-326350.
    PubMed     Abstract available


  114. SUN S, Yang Q, Zhou Q, Cao W, et al
    Long-term exposure to fine particulate matter and non-alcoholic fatty liver disease: a prospective cohort study.
    Gut. 2022;71:443-445.
    PubMed    


  115. CAO Z, Xie Q
    Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data.
    Gut. 2022;71:445-446.
    PubMed    


  116. FRANCQUE S, Wong VW
    NAFLD in lean individuals: not a benign disease.
    Gut. 2022;71:234-236.
    PubMed    


  117. YOUNES R, Govaere O, Petta S, Miele L, et al
    Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
    Gut. 2022;71:382-390.
    PubMed     Abstract available


  118. TREBICKA J, Gu W, de Ledinghen V, Aube C, et al
    Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease.
    Gut. 2022;71:402-414.
    PubMed     Abstract available


    January 2022
  119. TIAN S, Chu Y, Hu J, Ding X, et al
    Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT.
    Gut. 2022 Jan 27. pii: gutjnl-2021-325137. doi: 10.1136/gutjnl-2021-325137.
    PubMed     Abstract available


  120. SONDERGAARD JN, Sommerauer C, Atanasoai I, Hinte LC, et al
    CCT3-LINC00326 axis regulates hepatocarcinogenic lipid metabolism.
    Gut. 2022 Jan 12. pii: gutjnl-2021-325109. doi: 10.1136/gutjnl-2021-325109.
    PubMed     Abstract available


  121. BELLOMO G, Rainer C, Quaranta V, Astuti Y, et al
    Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis.
    Gut. 2022 Jan 12. pii: gutjnl-2021-325272. doi: 10.1136/gutjnl-2021-325272.
    PubMed     Abstract available


  122. JI F, Zhang J, Liu N, Gu Y, et al
    Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression.
    Gut. 2022 Jan 7. pii: gutjnl-2021-326050. doi: 10.1136/gutjnl-2021-326050.
    PubMed     Abstract available


  123. SCHULZ M, Trebicka J
    Acute-on-chronic liver failure: a global disease.
    Gut. 2022;71:5-6.
    PubMed    


  124. MEZZANO G, Juanola A, Cardenas A, Mezey E, et al
    Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis.
    Gut. 2022;71:148-155.
    PubMed     Abstract available


  125. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.
    Gut. 2022;71:156-162.
    PubMed     Abstract available


    December 2021
  126. VITALE A, Svegliati-Baroni G, Ortolani A, Cucco M, et al
    Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
    Gut. 2021 Dec 21. pii: gutjnl-2021-324915. doi: 10.1136/gutjnl-2021-324915.
    PubMed     Abstract available


  127. HUNG CT, Su TH, Chen YT, Wu YF, et al
    Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling.
    Gut. 2021 Dec 21. pii: gutjnl-2021-325065. doi: 10.1136/gutjnl-2021-325065.
    PubMed     Abstract available


  128. MACKEN L, Palaniyappan N, Verma S, Aithal G, et al
    Large volume paracentesis: to do or where to do?
    Gut. 2021;70:2401-2402.
    PubMed    


  129. BANG JY, Ward TJ, Guirguis S, Krall K, et al
    Radiology-guided percutaneous approach is superior to EUS for performing liver biopsies.
    Gut. 2021;70:2224-2226.
    PubMed    


  130. ARNORIAGA-RODRIGUEZ M, Mayneris-Perxachs J, Contreras-Rodriguez O, Burokas A, et al
    Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways.
    Gut. 2021;70:2283-2296.
    PubMed     Abstract available


  131. AFONSO MB, Rodrigues PM, Mateus-Pinheiro M, Simao AL, et al
    RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
    Gut. 2021;70:2359-2372.
    PubMed     Abstract available


  132. CARGILL Z, Cargill T, Lei B, Bekkali N, et al
    Uphill or downhill bleeding?
    Gut. 2021;70:2282-2348.
    PubMed    


    November 2021
  133. LIU DS, Frampton AE
    Plasma extracellular vesicles contain unannotated small RNA clusters suitable as biomarkers for detecting early hepatocellular carcinoma.
    Gut. 2021 Nov 19. pii: gutjnl-2021-325798. doi: 10.1136/gutjnl-2021-325798.
    PubMed    


    October 2021
  134. TRAUNER M, Fuchs CD
    Novel therapeutic targets for cholestatic and fatty liver disease.
    Gut. 2021 Oct 6. pii: gutjnl-2021-324305. doi: 10.1136/gutjnl-2021-324305.
    PubMed     Abstract available



  135. Correction: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
    Gut. 2021;70:e7.
    PubMed    


  136. WEBER S, Hellmuth JC, Scherer C, Muenchhoff M, et al
    Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.
    Gut. 2021;70:1925-1932.
    PubMed     Abstract available


  137. LIU T, Tan J, Wu M, Fan W, et al
    High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells.
    Gut. 2021;70:1965-1977.
    PubMed     Abstract available


  138. JUNG J, Loomba RR, Imajo K, Madamba E, et al
    MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Gut. 2021;70:1946-1953.
    PubMed     Abstract available


  139. MANKA P, Baba HA, Wedemeyer H, Kahraman A, et al
    Diet-refractory NASH in an elderly woman.
    Gut. 2021;70:1924-1945.
    PubMed    


    September 2021
  140. AN J, Kim HI, Oh B, Oh YJ, et al
    Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study.
    Gut. 2021 Sep 7. pii: gutjnl-2021-325844. doi: 10.1136/gutjnl-2021-325844.
    PubMed    


  141. JACHS M, Hartl L, Schaufler D, Desbalmes C, et al
    Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
    Gut. 2021;70:1758-1767.
    PubMed     Abstract available


    August 2021
  142. KHAMRI W, Gudd C, Liu T, Nathwani R, et al
    Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis.
    Gut. 2021 Aug 3. pii: gutjnl-2021-324071. doi: 10.1136/gutjnl-2021-324071.
    PubMed     Abstract available


  143. LIU J, Geng W, Sun H, Liu C, et al
    Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325189. doi: 10.1136/gutjnl-2021-325189.
    PubMed     Abstract available


  144. HEINRICH B, Gertz EM, Schaffer AA, Craig A, et al
    The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma.
    Gut. 2021 Aug 2. pii: gutjnl-2021-325288. doi: 10.1136/gutjnl-2021-325288.
    PubMed     Abstract available


    July 2021
  145. SHENG J, Zhang J, Wang L, Tano V, et al
    Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
    Gut. 2021 Jul 12. pii: gutjnl-2021-324339. doi: 10.1136/gutjnl-2021-324339.
    PubMed     Abstract available


  146. SIMON TG, Roelstraete B, Khalili H, Hagstrom H, et al
    Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Gut. 2021;70:1375-1382.
    PubMed     Abstract available


  147. WRZOSEK L, Ciocan D, Hugot C, Spatz M, et al
    Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury.
    Gut. 2021;70:1299-1308.
    PubMed     Abstract available


    June 2021
  148. PARK H, Yoon EL, Cho S, Jun DW, et al
    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
    Gut. 2021 Jun 14. pii: gutjnl-2021-325102. doi: 10.1136/gutjnl-2021-325102.
    PubMed    


  149. CHEUNG CCL, Goh D, Lim X, Tien TZ, et al
    Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2021 Jun 2. pii: gutjnl-2021-324280. doi: 10.1136/gutjnl-2021-324280.
    PubMed    


    May 2021
  150. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    PubMed     Abstract available


  151. ARMANDI A, Schattenberg JM
    NAFLD between genes and environment: what drives fibrogenesis?
    Gut. 2021;70:815-816.
    PubMed    


  152. MANTOVANI A, Petracca G, Beatrice G, Tilg H, et al
    Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.
    Gut. 2021;70:962-969.
    PubMed     Abstract available


    April 2021
  153. XIE Z, Gao Y, Ho C, Li L, et al
    Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.
    Gut. 2021 Apr 7. pii: gutjnl-2020-323014. doi: 10.1136/gutjnl-2020-323014.
    PubMed     Abstract available


  154. WANG X, He Y, Mackowiak B, Gao B, et al
    MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.
    Gut. 2021;70:784-795.
    PubMed     Abstract available


  155. ZHANG X, Coker OO, Chu ES, Fu K, et al
    Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Gut. 2021;70:761-774.
    PubMed     Abstract available


    March 2021
  156. GRANDER C, Schaefer B, Schwarzler J, Grabherr F, et al
    Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans.
    Gut. 2021;70:585-594.
    PubMed     Abstract available


    February 2021
  157. CHEN HN, Shu Y, Liao F, Liao X, et al
    Genomic evolution and diverse models of systemic metastases in colorectal cancer.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323703. doi: 10.1136/gutjnl-2020-323703.
    PubMed     Abstract available


  158. GOESER F, Munch P, Lesker TR, Lutz PL, et al
    Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity?
    Gut. 2021;70:438-440.
    PubMed    


  159. BARCENA-VARELA M, Paish H, Alvarez L, Uriarte I, et al
    Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
    Gut. 2021;70:388-400.
    PubMed     Abstract available


    January 2021
  160. BELLINGHAUSEN C, Pletz MW, Rupp J, Witzenrath M, et al
    Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia.
    Gut. 2021;70:221-222.
    PubMed    


  161. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
    Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
    Gut. 2021;70:219-221.
    PubMed    


  162. TANAKA Y, Shimanaka Y, Caddeo A, Kubo T, et al
    LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.
    Gut. 2021;70:180-193.
    PubMed     Abstract available


  163. HAGSTROM H, Thiele M, Roelstraete B, Soderling J, et al
    Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.
    Gut. 2021;70:170-179.
    PubMed     Abstract available


    December 2020
  164. VILY-PETIT J, Soty-Roca M, Silva M, Raffin M, et al
    Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease.
    Gut. 2020;69:2193-2202.
    PubMed     Abstract available


    November 2020
  165. FROST F, Kacprowski T, Ruhlemann M, Pietzner M, et al
    Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.
    Gut. 2020 Nov 9. pii: gutjnl-2020-322753. doi: 10.1136/gutjnl-2020-322753.
    PubMed     Abstract available


  166. LYU Z, Miao Q, Jiang P, Xiao X, et al
    Unexplained liver dysfunction in a young Chinese man with eosinophilia.
    Gut. 2020;69:1938-1987.
    PubMed    


    October 2020
  167. BASELLI GA, Dongiovanni P, Rametta R, Meroni M, et al
    Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.
    Gut. 2020;69:1855-1866.
    PubMed     Abstract available


  168. PIRONI L, Steiger E, Joly F, Wanten GJA, et al
    Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
    Gut. 2020;69:1787-1795.
    PubMed     Abstract available


    September 2020
  169. TARGHER G, Byrne CD, Tilg H
    NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
    Gut. 2020;69:1691-1705.
    PubMed     Abstract available


  170. SZAFRON D, Kim HS, Turin CG, Benzi E, et al
    Duodenal and liver lesions in an adult with generalised weakness.
    Gut. 2020;69:1-2.
    PubMed    


    February 2020
  171. SALERNO D, Chiodo L, Alfano V, Floriot O, et al
    Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637.
    PubMed     Abstract available


    January 2020
  172. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
    TGF-beta2 silencing to target biliary-derived liver diseases.
    Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.